化学
药效团
NAD+激酶
加合物
锡尔图因
部分
辅因子
立体化学
酶
烟酰胺腺嘌呤二核苷酸
电泳剂
烟酰胺
生物化学
烟酰胺
乙酰化
组合化学
赖氨酸
体外
突变
结构-活动关系
药物发现
蒂奥-
DNA
亲核细胞
西妥因1
蛋白质结构
多胺
DNA损伤
共价键
反应中间体
HEK 293细胞
作用机理
化学合成
三唑
细胞毒性
活动站点
代谢物
作者
Florian Friedrich,Marat Meleshin,Niklas Papenkordt,Lena Gaitzsch,Isabel Prucker,Marco Borsò,Jan Ruprecht,Christopher Vorreiter,Sabrina Rast,Lin Zhang,Matthias Schiedel,Wolfgang Sippl,Axel Imhof,Henning Jacob Jessen,Oliver Einsle,Mike Schutkowski,Manfred Jung
标识
DOI:10.1002/anie.202516782
摘要
Abstract Sirtuins (SIRTs) are nicotinamide adenine dinucleotide (NAD + )‐dependent lysine deacylases linked to key physiological and disease processes. Here, we report a new class of mechanism‐based 1,2,3‐triazole inhibitors that hijack SIRT catalysis by forming stalled triazolium– or triazole–ADP‐ribose (ADPR) adducts derived from the cofactor NAD + . These trapped adducts inhibit the enzyme without covalent protein modification, prompting us to term the compounds “Sirtuin Trapping Ligands” (SirTraps). X‐ray crystallography and kinetics, together with mass spectrometry confirming adduct formation both in vitro and in cellulo, reveal that the triazole N3 of peptide‐ and small‐molecule‐based SirTraps triggers nucleophilic attack at C1’ of the nicotinamide riboside moiety of NAD⁺, mimicking the first deacylation step. Adduct formation critically depends on precise triazole positioning within the acyl‐lysine channel and can be tuned through scaffold design, enabling potent and isoform‐selective inhibition. Unlike thiocarbonyl‐based NAD⁺‐targeting SIRT inhibitors, which may suffer from instability and off‐target effects, SirTraps combine high stability, synthetic accessibility, and structural tunability, while demonstrating nanomolar cellular target engagement confirmed by NanoBRET assays. Beyond SIRTs, this inhibition strategy may extend to other NAD⁺‐dependent enzymes, including ADP‐ribosyltransferases, opening new avenues for mechanism‐driven drug discovery.
科研通智能强力驱动
Strongly Powered by AbleSci AI